Table 2.

Baseline characteristics and treatment effects among classified groups.

	Group 2 (first Bevacizumab and then Ranibizumab or all Ranibizumab) n = 7	Group 3 (first Bevacizumab and then Aflibercept or all Aflibercept) n = 15	P value*
Average amount of IVI	3.86 (1.95)	3.73 (1.58)	P = .87
Average initial BCVA, ETDRS letter score, mean (SD)	55.43 (20.92)	41.4 (17.71)	P = .12
Average BCVA improvement, ETDRS letter score, mean (SD)	18.43 (16.95)	26.47 (17.52)	P = .93
Average initial CRT, μm, mean (SD)	548.29 (231.64)	516.33 (130.41)	P = .68
Average CRT improvement, μm, mean (SD)	262.43 (197.38)	237.67 (135.46)	P = .27

^*Two sample t test.

: BCVA = best-corrected distance visual acuity; CRT = central retina thickness; IVI = intravitreal injection, SD = standard deviations.